ALK and lung carcinoma: For instance, it was reported that for lung carcinoma, the rate of EGFR testing was the highest (>80%) while the rates of ALK and ROS1 testing were remarkably lower (Pennell et al., 2019), despite the fact that ALK and ROS1 mutations could occur in up to 10% of the cases (Song et al., 2017; Dang et al., 2020).